<DOC>
	<DOCNO>NCT00362986</DOCNO>
	<brief_summary>RATIONALE : Topical sunscreen may effective prevent skin rash cause treatment drug erlotinib cetuximab . It yet know whether topical sunscreen effective placebo prevent skin rash patient receive drug erlotinib cetuximab cancer . PURPOSE : This randomized phase III trial study topical sunscreen see well work compare placebo prevent skin rash patient receive drug erlotinib cetuximab cancer .</brief_summary>
	<brief_title>Topical Sunscreen Preventing Skin Rash Patients Receiving Drugs Such Erlotinib Cetuximab Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare incidence severity erlotinib- , cetuximab- , epidermal growth factor receptor inhibitor-induced skin rash development patient cancer treat prophylactic topical sunscreen v placebo . - Determine toxicity topical sunscreen v placebo patient . - Determine whether discontinuation treatment intervention follow rash development . OUTLINE : This multicenter , randomize , double-blind , placebo-controlled study . Patients stratify accord chemotherapy regimen ( first-line chemotherapy v ) , epidermal growth factor receptor ( EGFR ) inhibitor therapy ( small molecule v monoclonal antibody ) , concurrent medication increase sun hypersensitivity ( yes v ) , gender . Patients randomize 1 2 treatment arm . - Arm I : Patients apply sunscreen generously entire body twice daily 4 week . - Arm I : Patients apply placebo generously entire body twice daily 4 week . Patients complete self-reported questionnaire regard rash status baseline weekly 8 week . After completion study treatment , patient follow 8 week .</detailed_description>
	<mesh_term>Exanthema</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Sunscreening Agents</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer Receiving â‰¥ 1 follow epidermal growth factor receptor ( EGFR ) inhibitor treatment : Gefitinib Cetuximab Erlotinib Panitumumab ICR62 Matuzumab CI1033 EGFR treatment must begin within past 3 day No rash ( etiology ) study entry PATIENT CHARACTERISTICS : Able apply sunscreen face , trunk , extremity Able complete questionnaire ( ) No history allergic reaction severe intolerance sunscreen derivatives No history skin problem likely reoccur treatment Must avoid heavy sun exposure , especially hour noon 4 pm daily PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent tan bed usage No concurrent topical sunscreen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>dermatologic complication</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>